Previous 10 | Next 10 |
Gainers: Grove (NASDAQ:GRVI) +62%. NRx Pharmaceuticals (NASDAQ:NRXP) +35%. Connect Biopharma (NASDAQ:CNTB) +23%. Huttig Building Products (NASDAQ:HBP) +20%. KORE (NYSE:KORE) +20%. DarioHealth (NASDAQ:DRIO) +19%. Broadwind (NASDAQ:BWEN) +19%. Cemtrex (NASDAQ:CETX) +17%. Annovis (NYSE:ANVS) +17...
Shares of BioXcel Therapeutics (NASDAQ: BTAI) were sinking 15.2% as of 11:25 a.m. EDT on Thursday. The decline came after the company's regulatory filing to the Securities and Exchange Commission revealed that chief commercial officer William P. Kane Jr. had resigned on Oct. 8. ...
Gainers: Grove (NASDAQ:GRVI) +63%, NRx Pharmaceuticals (NASDAQ:NRXP) +34%, DarioHealth (NASDAQ:DRIO) +22%, Connect Biopharma (NASDAQ:CNTB) +21%, Annovis Bio (NYSE:ANVS) +15%. Losers: Jasper Therapeutics (NASDAQ:JSPR) -20%, PLx Pharma (NASDAQ:P...
Management to showcase AI platform to develop potential treatments for neuropsychiatric disorders Company to introduce BXCL502 program and discuss expansion opportunities for lead program, BXCL501 Event to take place today from 12:00 p.m. – 2:00 p.m. EST NEW...
BXCL701 plus KEYTRUDA® (pembrolizumab) demonstrates encouraging anti-tumor activity in heavily pre-treated mCRPC patients with adenocarcinoma BXCL701 combination continues to exhibit favorable safety profile; patient enrollment continues as per protocol NEW HAVEN, Con...
NEW HAVEN, Conn., Sept. 12, 2021 (GLOBE NEWSWIRE) -- BioXcel Therapeutics, Inc. (“BioXcel” or the “Company”) (Nasdaq: BTAI), a clinical-stage biopharmaceutical company utilizing artificial intelligence approaches to develop transformative medicines in neuroscienc...
Live webcast, Revolutionizing Drug Discovery and Development Through AI , to be held from 12:00 PM ET – 2:00 PM ET NEW HAVEN, Conn., Sept. 09, 2021 (GLOBE NEWSWIRE) -- BioXcel Therapeutics, Inc. (Nasdaq: BTAI) (“BioXcel” or the “Company”), a clinic...
Any investor who looks at the stock price chart during this year 2021 will be shadowed by the sharp drop that it presents. Only considering the BXCL501 program we can affirm that BioXcel currently presents an excellent investment opportunity in the medium/long term. Next year 2022...
BioXcel Therapeutics, Inc. (BTAI) Q2 2021 Results Conference Call August 10, 2021 08:30 AM ET Company Participants Dr. Vimal Mehta - CEO Richard Steinhart - CFO Will Kane - Chief Commercial Officer Dr. Vince O’Neill - Chief Medical Officer Dr. Frank Yocca - Chief Scientific Officer Dr....
Phase 3 study of BXCL501 for the acute treatment of agitation associated with dementia expected to begin in Q4 2021 PDUFA date of January 5, 2022 assigned to BXCL501 NDA for the acute treatment of agitation associated with schizophrenia and bipolar disorders I & II Dat...
News, Short Squeeze, Breakout and More Instantly...
BioXcel Therapeutics Inc. Company Name:
BTAI Stock Symbol:
NASDAQ Market:
BioXcel Therapeutics Inc. Website:
Focused market-access strategy generates estimated net revenue of approximately $1.1 million, highest quarterly net revenue since commercial launch Represents 90% increase from the prior quarter and 141% increase from the second quarter of 2023 NEW HAVEN, Conn., July 16, 2024 (GLO...
Study achieved its objective and demonstrated no evidence of tachyphylaxis, tolerance, or withdrawal with 180 mcg dose (highest approved dose) For each episode occurring over seven days, a reduction in agitation was observed and no serious adverse events were reported following treatmen...
NEW HAVEN, Conn., May 28, 2024 (GLOBE NEWSWIRE) -- BioXcel Therapeutics, Inc. (Nasdaq: BTAI), a biopharmaceutical company utilizing artificial intelligence to develop transformative medicines in neuroscience and immuno-oncology, today announced that CEO Vimal Mehta, Ph.D., will present at the Jef...